Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Drug Safety|February 14, 2024
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic StudyMonica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, et al.
Breast Cancer Research and Treatment|August 27, 2025
Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patientsJenny Wei, Ashley Aller, Shiyun Zhu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
Pharmacotherapy|September 4, 2019
Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug AdministrationMonica A Muñoz, Chris Delcher, Gerald J Dal Pan, et al.
JAMA Network Open|July 28, 2025
CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid TreatmentNoor A Nahid, Caitrin W McDonough, Yu-Jung Jenny Wei, et al.
Alzheimer'S Research & Therapy|April 22, 2021
Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementiaYu-Jung Jenny Wei, Siegfried Schmidt, Cheng Chen, et al.
Journal of the American Medical Directors Association|February 27, 2025
Outcomes of Discontinuing Long-Term Opioid Therapy among Older Cancer Survivors in Long-Term Care SettingsYu-Jung Jenny Wei, Almut G Winterstein, Siegfried Schmidt, et al.
Clinical Kidney Journal|August 14, 2024
Safety and efficacy of very low calorie diet in patients receiving haemodialysis therapyJulie E Woods, Anne Snelson, Joanne Kok, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Pageof 7